ArticleNature microbiology2018
Antibiotic-resistant bacteria show widespread collateral sensitivity to antimicrobial peptides.
Article in Nature microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 184 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
184 citing papers in PubMed.
- Adaptive Response ofAntibiotics (Basel, Switzerland) · 2026Article
- Gramicidin D as a Multi-Target Antimicrobial Against Staphylococcus aureus: Biofilm Disruption, Virulence Attenuation, Antibiotic Potentiation, and Protein-Peptide Docking Insight.Probiotics and antimicrobial proteins · 2026Article
- Antibiotic-induced gut microbiome dysbiosis: risks and strategies for mitigation.The EMBO journal · 2026Review
- Antimicrobial peptides for bacterial infections and their biomedical applications.Discover nano · 2026Review
- Mutational basis of ceftazidime-borrelidin A collateral sensitivity in Escherichia coli.G3 (Bethesda, Md.) · 2026Article
- Rationally Engineered D-Amino Acid Peptide DT7-3 Combats Multidrug-ResistantMicroorganisms · 2026Article
- Combinations of colistin and bacteriocins prevent the selection of colistin resistance in Acinetobacter baumannii.Communications biology · 2026Article
- Evolutionary drivers of divergent collateral sensitivity responses during antibiotic therapy.Nature ecology & evolution · 2026Review
- Molecular mechanisms of disinfectant resistance inJAC-antimicrobial resistance · 2026Article
- tsAMP: a strain-level antimicrobial peptide identification framework based on large language models and pathogen genomic variation.Frontiers in microbiology · 2026Article
- Utilizing Proteolytic-Resistant Nano-Short Peptide Based on Naphthyl Tail-Anchored to Combat Bacterial Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Nanoplatforms in sepsis storm: Multimodal synergy for precision immunomodulation and pathogen neutralizations.Pharmaceutical science advances · 2025Review
- Turn-engineering tunes the conformational rigidity of β-hairpin AMPs in achieving membrane selectivity and killing drug-resistant ESKAPE pathogens.Chemical science · 2025Article
- Minimal gene signatures enable high-accuracy prediction of antibiotic resistance in Pseudomonas aeruginosa.NPJ systems biology and applications · 2025Article
- Tutorial: guidelines for the use of machine learning methods to mine genomes and proteomes for antibiotic discovery.Nature protocols · 2025Review
- A unified model of transient poration induced by antimicrobial peptides.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Invariant set theory for predicting potential failure of antibiotic cycling.Infectious Disease Modelling · 2025Article
- Micro- and Nano-Bots for Infection Control.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- Cross resistance emergence to polymyxins in Acinetobacter baumannii exposed in vitro to an antimicrobial peptide.npj antimicrobials and resistance · 2025Article
- Lead Informed Artificial Intelligence Mining of Antitubercular Host Defense Peptides.Biomacromolecules · 2025Article
124 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
Antimicrobial peptides are promising alternative antimicrobial agents. However, little is known about whether resistance to small-molecule antibiotics leads to cross-resistance (decreased sensitivity) or collateral sensitivity (increased sensitivity) to antimicrobial peptides. We systematically addressed this question by studying the susceptibilities of a comprehensive set of 60 antibiotic-resistant Escherichia coli strains towards 24 antimicrobial peptides. Strikingly, antibiotic-resistant bacteria show a high frequency of collateral sensitivity to antimicrobial peptides, whereas cross-resistance is relatively rare. We identify clinically relevant multidrug-resistance mutations that increase bacterial sensitivity to antimicrobial peptides. Collateral sensitivity in multidrug-resistant bacteria arises partly through regulatory changes shaping the lipopolysaccharide composition of the bacterial outer membrane. These advances allow the identification of antimicrobial peptide-antibiotic combinations that enhance antibiotic activity against multidrug-resistant bacteria and slow down de novo evolution of resistance. In particular, when co-administered as an adjuvant, the antimicrobial peptide glycine-leucine-amide caused up to 30-fold decrease in the antibiotic resistance level of resistant bacteria. Our work provides guidelines for the development of efficient peptide-based therapies of antibiotic-resistant infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.